MFG
RPRX icon

Merit Financial Group’s Royalty Pharma RPRX Stock Holding History

Merit Financial Group’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1M Buy
17,896
+3,071
+21% +$160K 0.01% 1072
2026
Q1 		$711K Buy
14,825
+2,250
+18% +$98.5K 0.01% 1159
2025
Q4 		$486K Buy
12,575
+3,425
+37% +$131K ﹤0.01% 1323
2025
Q3 		$323K Buy
9,150
+307
+3% +$11.1K ﹤0.01% 1405
2025
Q2 		$319K Buy
8,843
+746
+9% +$24.7K ﹤0.01% 1312
2025
Q1 		$252K Buy
+8,097
New +$257K ﹤0.01% 1195

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Merit Financial Group's RPRX Position: Q2 2026 in Review

Merit Financial Group increased its Royalty Pharma (RPRX) stake by 21% in Q2 2026, buying an estimated $160K and bringing the position to 17,896 shares worth $1M. The position accounts for 0.01% of the portfolio, ranked #1072.

Merit Financial Group first reported a position in RPRX in Q1 2025 and has held it in 6 quarters since. 645 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Merit Financial Group held 17,896 shares of Royalty Pharma worth $1M as of Q2 2026.
  • Merit Financial Group bought 3,071 Royalty Pharma shares in Q2 2026, an estimated $160K.
  • Royalty Pharma made up 0.01% of Merit Financial Group's portfolio in Q2 2026, its #1072 holding.
  • Merit Financial Group first reported a position in Royalty Pharma in Q1 2025 and has held it in 6 quarters since.
  • 645 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Merit Financial Group's 13F filing for Q2 2026, filed 17 Jul 2026.